Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, October 31, 2012
Aesica, the global contract manufacturing organisation (CMO), announces that it has won the European Outsourcing award for ‘best acquisition’ following the successful acquisition and integration of three different UCB sites – at Monheim and Zwickau ...
read more
Aesica, the global contract development and manufacturing organisation (CDMO), is pleased to announce the 20th anniversary of its site located at Zwickau in Germany. The facility possesses multiple solid oral dosage form technologies and service ...
read more
Thursday, December 17, 2020
Aeterna Zentaris has entered into a licensing agreement with Consilient Health for the commercialization in Europe and the United Kingdom of macimorelin.
read more
Robert Broeze will retire on March 5th, 2019 after a 35-year career in the biopharmaceutical industry.
read more
Monday, November 15, 2021
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced Jean-Baptiste Agnus has been appointed as the company’s Chief Business Officer (CBO). In this position, he is responsible for ...
read more
AGC Biologics will supply bulk drug substance for the launch of Portola Pharmaceuticals' Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo].
read more
Monday, December 16, 2019
AGC Biologics is expanding its CDMO services with plasmid DNA (pDNA) offerings from its Heidelberg site in Germany.
read more
Tuesday, January 24, 2023
AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site.
read more
Wednesday, February 09, 2022
AGC Biologics announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility.
According to a recent news release from Pfizer and BioNTech, the ...
read more
AGC Biologics, a biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, Colorado, ...
read more
AGC Biologics is partnering with clinical-stage biotech company Molecular Partners to develop a new class of custom-built protein therapeutics known as DARPin.
read more
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with BioNTech SE (Nasdaq BNTX) to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech ...
read more
AGC Chemicals now offers small-molecule API contract manufacturing services.
read more
AGC has announced the completion of its acquisition of Spain's synthetic pharmaceutical active ingredient manufacturer, Malgrat Pharma Chemicals, S.L.U. (MPC).
read more
Tuesday, January 15, 2019
AGC has entered into an agreement with Boehringer Ingelheim to acquire its subsidiary Malgrat Pharma Chemicals, S.L.U. (MPC).
read more